US biotechnology companies developing innovative medicines increasingly target the European market for regulatory approval and subsequent patient access. In both the European Union (EU) and the United Kingdom (UK), recent procedural reforms have introduced requirements and structured pathways that necessitate or strongly incentivise the simultaneous or parallel preparation of Marketing Authorisation Application (MAA) dossiers and Health Technology Assessment (HTA) dossiers.
These developments represent a shift from traditional sequential models (regulatory review followed by HTA) toward greater temporal and evidentiary coordination between benefit-risk assessment for authorisation and evaluation of relative clinical effectiveness and value for reimbursement decisions.
This article outlines the key changes, their scientific and procedural implications, and the resulting strategic requirements for sponsors.
The EU HTA Regulation and Joint Clinical Assessments
Regulation (EU) 2021/2282 on Health Technology Assessment entered into application on 12 January 2025 for initial product categories, beginning with new medicines for cancer treatment and advanced therapy medicinal products (ATMPs), with phased expansion thereafter. It establishes mandatory Joint Clinical Assessments (JCAs) at EU level to provide a harmonised scientific analysis of relative clinical effectiveness. These JCAs inform but do not replace national HTA processes, which retain authority over non-clinical aspects, economic evaluation, and reimbursement decisions.
The JCA procedure runs in parallel with the centralised MAA procedure at the European Medicines Agency (EMA). Upon validation of an MAA submission to the EMA, health technology developers must simultaneously transmit the Summary of Product Characteristics (SmPC) and clinical overview to the HTA secretariat. This information supports scoping, including determination of the Population, Intervention, Comparator, and Outcomes (PICO) framework by appointed assessors from Member State HTA bodies.
Sponsors are then required to prepare and submit a dedicated JCA dossier according to defined timelines following scoping. This preparation occurs concurrently with ongoing EMA review activities, including responses to any List of Questions (LoQ), clock-stops, or other interactions. The resulting dual workload demands rigorous coordination to maintain consistency in clinical data presentation, address potential differences in evidence interpretation between regulatory benefit-risk and HTA relative-effectiveness perspectives, and avoid inconsistencies that could generate supplementary queries in either process.
Early Joint Scientific Consultations (JSCs) between developers, EMA, and HTA bodies are available to align study design elements (e.g., endpoints, comparators, subgroups, patient-reported outcomes) with the needs of both frameworks from the development phase onward.
The UK MHRA-NICE Aligned Pathway
In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) and National Institute for Health and Care Excellence (NICE) have implemented an Aligned Pathway (with coordinated processes operational from 2026). This framework facilitates parallel review timelines with the explicit aim of enabling publication of marketing authorisation decisions and HTA guidance to coincide where timelines are optimised.
Key operational features include early product registration via UK PharmaScan (recommended at least three years prior to expected authorisation), coordinated scheduling of NICE appraisals relative to MHRA milestones, and the option for NICE draft guidance to be issued with recommendations contingent on grant of the marketing authorisation. Dossiers are submitted independently to each body, but priority scheduling and milestone coordination reduce the historical gap between authorisation and HTA recommendations.
An integrated scientific advice service supports developers through a single process, providing coordinated input on evidence requirements for both regulatory authorisation and HTA. This helps optimise pivotal trial design and supplementary evidence generation (e.g., real-world data, economic modelling inputs) to meet the distinct but increasingly aligned needs of licensing and value assessment.
The pathway preserves independent decision-making by MHRA (quality, safety, efficacy) and NICE (clinical and cost-effectiveness) while delivering more predictable and accelerated timelines to NHS access.
Scientific and Operational Implications for Sponsors
These reforms create several interconnected requirements:
- Evidence generation must serve dual purposes from an early stage. Clinical development programmes should incorporate endpoints, comparators, and data collection strategies that address both EMA/MHRA benefit-risk criteria and HTA preferences for relative effectiveness, patient-relevant outcomes, and value demonstration. Divergence in PICO scoping or evidence preferences between processes can necessitate additional analyses or studies if not anticipated.
- Dossier preparation becomes concurrent rather than sequential. Sponsors must manage overlapping timelines for MAA modules/responses and HTA dossiers (JCA or national submissions). This increases demands on project management, cross-functional data synthesis, and quality control to ensure scientific consistency while accommodating differing methodological emphases (e.g., strict adherence to pivotal trial data for authorisation versus allowance for indirect comparisons or real-world evidence in HTA).
- Proactive gap analysis and scenario planning are essential. Early identification of evidence gaps relative to both regulatory and HTA expectations, combined with modelling of potential PICO variations, reduces the risk of delays, additional data requests, or suboptimal positioning in value assessments.
- Cross-functional integration is required. Traditional separation between regulatory affairs teams (focused on authorisation) and HEOR/HTA teams (focused on market access) creates inefficiencies and risks in a parallel environment. Successful navigation depends on unified strategies that align clinical, regulatory, and health economic evidence planning.
US sponsors without extensive prior European experience may face particular challenges in anticipating these interactions, given differences from FDA-centric development paradigms.
Strategic Imperative: Integrated Regulatory and HEOR/HTA Capabilities
The procedural alignment of regulatory and HTA processes in both the EU and UK elevates the importance of expertise that transcends traditional functional silos. Effective support now requires integrated capabilities that treat regulatory authorisation and HTA dossier preparation as interconnected components of a single evidence and strategy continuum, rather than sequential workstreams.
Pharma Design Limited is one of few consultancy businesses that integrates Regulatory and HEOR/HTA according to the nature of these changes. Its model is structured specifically around the concurrent requirements introduced by the EU HTA Regulation (parallel JCA and EMA processes) and the UK aligned pathway (coordinated MHRA-NICE timelines and integrated advice). This enables seamless alignment of regulatory and market access strategies across Europe, optimising evidence consistency, minimising duplication, and supporting sponsors through the full continuum from development planning to simultaneous dossier readiness.
Conclusion
The EU Joint Clinical Assessment framework and the UK MHRA-NICE Aligned Pathway mark a substantive evolution toward greater coordination between regulatory science and health technology assessment. For US biotech companies, these changes reward early, integrated planning of evidence strategies and dossier preparation while increasing the cost of misalignment.
Sponsors that adapt their internal processes and external partnerships to this parallel environment are better positioned to achieve timely authorisations and efficient progression to reimbursement decisions. Specialised support that embeds regulatory-HTA integration as a core operating principle offers a direct response to the scientific and procedural demands of the current European landscape.